Mar 30, 2023 / 05:00PM GMT
Ram Selvaraju - H.C. Wainwright & Co., LLC - Analyst
Hello, everyone, and welcome to this next in our series of fireside chats as part of the H.C. Wainwright conference focusing on inflammatory skin diseases within the context of dermatology. My name is Ram Selvaraju. I'm a managing director and senior healthcare equity research analyst here at H.C. Wainwright.
Our next participating company is Aclaris Therapeutics, traded on the NASDAQ under the ticker symbol ACRS. We cover Aclaris with a buy rating and 12-month price target of $43 per share. I'm joined here by Doug Manion, Chief Executive Officer.
Doug, a very warm welcome to you.
And I think if we could perhaps start with your giving us an overview of Aclaris and its history within dermatology, dermatology-focused drug development, and its overall expertise in advancing molecules for these kinds of indications, I think that would be a great place to get started.
Doug Manion - Aclaris Therapeutics, Inc. - President, CEO, & Director
Yes, it's actually great to see you, Ram,
Aclaris Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers